Electrocardiographic abnormalities among dialysis naïve chronic kidney disease patients in Ilorin Nigeria

Annals of African Medicine

Volumn 11, Issue 1, 2012, Pages 21-26

  Chijioke, A ^a   Makusidi, A M ^a   Kolo, P M ^a  

^a UNIVERSITY OF ILORIN   (Nigeria)

Author keywords

Chronic kidney disease; Electrocardiogram abnormalities; Ilorin; Nigeria

Indexed keywords

ADULT; ANEMIA; ARTICLE; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DIABETIC NEPHROPATHY; EARLY DIAGNOSIS; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE EXTRASYSTOLE; HEMODIALYSIS PATIENT; HOSPITAL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NIGERIA; PHYSICIAN; PREVALENCE; PROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ADULT; ANEMIA; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DELAYED DIAGNOSIS; DIABETIC NEPHROPATHIES; ELECTROCARDIOGRAPHY; FEMALE; GLOMERULONEPHRITIS; HEART ATRIA; HEART DISEASES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NIGERIA; PREVALENCE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SEX FACTORS;

EID: 84855797089     PISSN: 15963519     EISSN: 09755764     Source Type: Journal    
DOI: 10.4103/1596-3519.91011     Document Type: Article

References (48)

1. Cohen MV, Diaz P, Schemer J. Echocardiograph assessment of left ventricular function in patients with chronic uraemia. Clin. Nephrol 1979;12:156-62. (Pubitemid 10198115)
2. Cohen JL, Barcoch B, Segal KR, Batuman V. Two - dimensional echocardiography finding in patients on haemodialysis for more than six months. Am J Cardiol 1987;60:743-5. (Pubitemid 17154636)
3. Blayer AJ, Tell GS, Evans GW, Ehinger WH, Burkart JM. Survival of patient undergoing renal replacement therapy in one centre with special emphasis on racial differences. Am J Kidney Dis 1996;28:72-81. (Pubitemid 26231469)
4. USRDS 2004. Annual Data Reports: Atlas of End-stage- Renal disease in the United state national institute of health, national institute of diabetes and digestive and kidney disease. Bethesda: MD,. 2004.
5. Levey AS. Controlling the epidemic of cardiovascular disease in chronic kidney disease: where do we start.? Am J Kid Dis 1998;32 (suppl):S5-13. (Pubitemid 28527261)
6. Majunath G, Tioshiout J, Coresh J, Macleod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003;63:1121-9. (Pubitemid 36315592)
7. Collins AJ, Li S, Gilbertson DJ, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the medicare population. Kidney Int Suppl 2003;87:S24-31. (Pubitemid 37315504)
8. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9 (12 Suppl): S16-23.
9. Hung J, Harris PJ, Uren RF, Tiller DJ. Uraemic cardiomyopathy - effect of haemodialysis on left ventricular function in end stage renal failure. N Engl J Med 1980;302:547-51. (Pubitemid 10184279)
10. Iseki K, Ikemiya Y, Iseki C, Takishita S. Protenuria and the risk of developing end stage disease. Kidney Int 2003;63: 1468-74. (Pubitemid 36350012)
11. Weiner DE, Tighcourt H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all - cause mortality. A pooled analysis of community based studies. J Am Soc Nephrol 2004;15:1307-15. (Pubitemid 38526012)
12. Robert NF, Anne MM, Shuling L, Charles AH, Marshall AM, Paul WE, Allan JC. Chronic kidney disease and the risk cardiovascular disease, replacement therapy and death in the United states medicare population. 1998-1999. J Am Soc Nephrol 2005;16:489-95.
13. Kher V. End stage renal disease in developing countries. Kidney Int 2002;62:350-62. (Pubitemid 34754084)
14. Beaubien ER, Pulypchuk GB, Akhtar J, Biem HJ. Value to corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis 2002;39: 834-42. (Pubitemid 34263359)
15. Nwankwo EA, Ummate I, Wudiri W. Prevalence of electrocardiographic left ventricular hypertrophy among incident dialysis patients in Maiduguri Nigeria. Res J Medicine & Med Sci 2007;2:1-4.
16. Perfrey PS, Forley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10:1606-15.
17. NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcome Quality Initiative). Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Part 5 evaluation of laboratory measurement for clinical assessment of kidney disease. Am J Kidney Dis 2002;39:76-110.
18. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease improving global outcomes (KDIGO). Kidney Int 2005;67:2089-100. (Pubitemid 41623371)
19. Chijioke A, Adeniyi AB. End stage renal disease: Racial differences. Orient J Med 2003;15:24-31.
20. McCulloch CE, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events and hospitalization. N Engl J Med 2004;351:1296-305.
21. Franklin SS, Khan SA, Whong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999;100:354-60. (Pubitemid 29362404)
22. Paul R, Chris J, Nick D, Sara B, Premila W, Jonathan G, Sue G, Linda B, Juan M, Charlie T. Late referral for end stage renal disease: A region wide survey in the southwest of England. Nephrol Dial Transpl 2002;17:1252-9.
23. Jungers P, Zingraft J. Detrimental effect of late referral in patients with chronic renal failure: A case control study. Kidney Int 1993;43:S170-3.
24. Oyediran AB, Akinkugbe OO. Chronic renal failure in Nigeria. Trop. Geog. Med. J.1970;22:41-45
25. Akinsola W, Odesanmi WO, Oguniyi JO, Ladipo GO. Diseases causing chronic renal failure in Nigerians: A prospective study of 100 cases. Afr J Med Med Sci 1989;18:131-7. (Pubitemid 19142054)
26. Salako BL, Kadiri S, Etok V, Adesola K. The clinical and laboratory evaluation of patients with chronic renal failure in UCH Ibadan before their first dialysis. Dokita 1995;22:56-9.
27. Iseki K, Kawazeo N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa Japan. Kidney Int 1993;43:404-9. (Pubitemid 23162834)
28. Walker WG, Neaton JD, Cutler JA, Newwirth R, Cohen JD. Renal function change in hypertensive members of Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA 1992;268:3085-91.
29. Adeera L, Ognjenka D, Brandan B, Ellen B, Euan C, Jean E, Kailash J, David M, Sheldron T, Joel S, Christopher T. Cardiovascular disease in patients with CKD: Getting to the heart of the matter. Am J Kidney Dis 2001;38: 1398-407.
30. Collins AJ. Cardiovascular mortality in end stage renal disease. Am J Med Sci 2003;325:163-7. (Pubitemid 36437989)
31. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and anti-hypertensive drug class on progression of hypertensive kidney disease: Results from AASK trial. JAMA 2002;288:2421-31. (Pubitemid 35340538)
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52. (Pubitemid 37553153)
33. NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcome Quality Initiative). Clinical practice guidelines on hypertension and anti-hypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43(5 suppl):S1-290.
34. Peratta CA, Hicks LS, Chertow GM, Ayanian JZ, Vittinghoff E, Lin F, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension 2005;45:1119-24. (Pubitemid 40770315)
35. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end stage renal disease in the united states. J Am Soc Nephrol 2003;14:2902-7. (Pubitemid 37305653)
36. McClellan W, Aronoff SL, Botton WK, Hood S, Lorber DL, Tang LK, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anaemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-10. (Pubitemid 39361354)
37. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic kidney disease. What Do We Know?. What do we need to learn? Where do we go from here? National kidney foundation task force on cardiovascular disease. Am J Kidney Dis 1998;32:853-906. (Pubitemid 28516321)
38. Collins AJ, Li S, Peter W, Ebben J, Roberts T, Jennie ZMA, Manning W. Death, Hospitalization an Economic Association among Incident Haemodialysis Patients with haematocrit Value of 36-39%. J Am Soc Nephrol 2001;12:2465-73.
39. Francois M, Edmund GL, Carlo B, Nancy LL, Lazarus JM, Kenneth B, William FO. Anaemia in Haemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997;8:1921-9. (Pubitemid 28185451)
40. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on mortality and morbidity: The Experience of the Lombardy Dialysis Registry. Nephrol Dial Transpl 1998;13:1642-4. (Pubitemid 28306788)
41. Colllins XM, Ebben MJ. Heamatocrit level and associated mortality in haemodialysis patients. J Am Soc Nephrol 1998;10:610.
42. Cannella G, La Canna G, Sandrini M, Gaggiotti M, Nordio G, Movilli E, Maiorca R. Renormalization of high cardiac output and of left ventricular size following long-term recombinant erythropoietin treatment of aneamia in dialyzed ureamic patients. Clin Nephrol 1990;34:272-8.
43. Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, et al. Electrocardiographic abnormalities and ureamic cardiomyopathy. Kidney Int 2005;67:217-26.
44. Oberman A, Prineas RJ, Larson JC, Lacroix A, Lasser NL. Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women (The Women's Health Initiative). Am J Cardiol 2006;97:512-9. (Pubitemid 43190042)
45. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by Losartan compared with Atenolol: The Losartan intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004;110:1456-62. (Pubitemid 39238023)
46. Klingbell AU, Schneider M, Martus P, Messerli FH, Schmieder RE. Meta-analysis of effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41-6. (Pubitemid 36831120)
47. Kieldsen SE, Dahlof B, Devieux RB, Julius S, Aurup P, Edelman J, et al. Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491-8.
48. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial Change in Echocardiograph Parameters and Cardiac Outcome in ESRD. J Am Soc Nephrol 1998;9:249.